Clinical prospects for new thyroid hormone analogues

Cory A. Ocasio, Thomas (Tom) Scanlan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of review: Scientists have been studying liver-selective thyroid hormone analogues developed between the late 1980s through the late 1990s to validate their utility in treating hypercholesterolemia, diabetes, atherosclerosis, and obesity. Several thyromimetics with agonistic or antagonist properties have recently been developed and their clinical utility is being explored. This review presents the progress of several thyromimetics with potential clinical utility and provides an assessment of the potential of second-generation thyromimetics with varying pharmacologic profiles. Recent findings: GC-1 exhibits cholesterol-lowering effects in hypothyroid mice, cholesterol-fed rats, and cynomolgus monkeys. DITPA (3,5-diiodothyropropionic acid) is currently being investigated for use in treating congestive heart failure. In rat and rabbit postinfarction models, DITPA administration in combination with captopril or as monotherapy caused an increase in cardiac output and a decrease in left ventricular end-diastolic pressure without chronotropic or significant metabolic effects. DITPA treatment induces arteriolar growth and improves maximal perfusion potential of hypertrophied myocardium surviving a myocardial infarction. Thyroid hormone receptor-β-selective agonists, GC-24, KB-141, and KAT-681, as well as the thyroid hormone receptor-α-selective and thyroid hormone receptor-β-selective antagonists dronedarone and NH-3 show promise in treating hypercholesterolemia, hyperlipidemia, hepatocarcinogenesis, heart failure, and hyperthyroidism. Summary: Thyroid hormone receptors orchestrate a diverse array of physiologic activities in an isoform-specific manner. These activities include fetal and postnatal development, regulation of lipid inventory, and effects on cardiac performance. As a result, thyroid hormone analogues that selectively modulate thyroid hormone receptor isoforms serve as potential therapeutics in treating several metabolic and cardiac-related diseases.

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalCurrent Opinion in Endocrinology and Diabetes
Volume12
Issue number5
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Thyroid Hormone Receptors
Thyroid Hormones
Hypercholesterolemia
Protein Isoforms
Heart Failure
Cholesterol
Macaca fascicularis
Captopril
Hyperthyroidism
Fetal Development
Hyperlipidemias
Cardiac Output
Heart Diseases
Atherosclerosis
Myocardium
Perfusion
Obesity
Myocardial Infarction
Hormones
Rabbits

Keywords

  • Cardiac sparing
  • Hypercholesterolemia
  • Isoform specific
  • Liver selective
  • Thyroid hormone analogues
  • Thyroid hormone receptor
  • Thyromimetics

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Clinical prospects for new thyroid hormone analogues. / Ocasio, Cory A.; Scanlan, Thomas (Tom).

In: Current Opinion in Endocrinology and Diabetes, Vol. 12, No. 5, 10.2005, p. 363-370.

Research output: Contribution to journalArticle

@article{2ddddf7f64bd452a949c891f21137d17,
title = "Clinical prospects for new thyroid hormone analogues",
abstract = "Purpose of review: Scientists have been studying liver-selective thyroid hormone analogues developed between the late 1980s through the late 1990s to validate their utility in treating hypercholesterolemia, diabetes, atherosclerosis, and obesity. Several thyromimetics with agonistic or antagonist properties have recently been developed and their clinical utility is being explored. This review presents the progress of several thyromimetics with potential clinical utility and provides an assessment of the potential of second-generation thyromimetics with varying pharmacologic profiles. Recent findings: GC-1 exhibits cholesterol-lowering effects in hypothyroid mice, cholesterol-fed rats, and cynomolgus monkeys. DITPA (3,5-diiodothyropropionic acid) is currently being investigated for use in treating congestive heart failure. In rat and rabbit postinfarction models, DITPA administration in combination with captopril or as monotherapy caused an increase in cardiac output and a decrease in left ventricular end-diastolic pressure without chronotropic or significant metabolic effects. DITPA treatment induces arteriolar growth and improves maximal perfusion potential of hypertrophied myocardium surviving a myocardial infarction. Thyroid hormone receptor-β-selective agonists, GC-24, KB-141, and KAT-681, as well as the thyroid hormone receptor-α-selective and thyroid hormone receptor-β-selective antagonists dronedarone and NH-3 show promise in treating hypercholesterolemia, hyperlipidemia, hepatocarcinogenesis, heart failure, and hyperthyroidism. Summary: Thyroid hormone receptors orchestrate a diverse array of physiologic activities in an isoform-specific manner. These activities include fetal and postnatal development, regulation of lipid inventory, and effects on cardiac performance. As a result, thyroid hormone analogues that selectively modulate thyroid hormone receptor isoforms serve as potential therapeutics in treating several metabolic and cardiac-related diseases.",
keywords = "Cardiac sparing, Hypercholesterolemia, Isoform specific, Liver selective, Thyroid hormone analogues, Thyroid hormone receptor, Thyromimetics",
author = "Ocasio, {Cory A.} and Scanlan, {Thomas (Tom)}",
year = "2005",
month = "10",
doi = "10.1097/01.med.0000177422.57988.b2",
language = "English (US)",
volume = "12",
pages = "363--370",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinical prospects for new thyroid hormone analogues

AU - Ocasio, Cory A.

AU - Scanlan, Thomas (Tom)

PY - 2005/10

Y1 - 2005/10

N2 - Purpose of review: Scientists have been studying liver-selective thyroid hormone analogues developed between the late 1980s through the late 1990s to validate their utility in treating hypercholesterolemia, diabetes, atherosclerosis, and obesity. Several thyromimetics with agonistic or antagonist properties have recently been developed and their clinical utility is being explored. This review presents the progress of several thyromimetics with potential clinical utility and provides an assessment of the potential of second-generation thyromimetics with varying pharmacologic profiles. Recent findings: GC-1 exhibits cholesterol-lowering effects in hypothyroid mice, cholesterol-fed rats, and cynomolgus monkeys. DITPA (3,5-diiodothyropropionic acid) is currently being investigated for use in treating congestive heart failure. In rat and rabbit postinfarction models, DITPA administration in combination with captopril or as monotherapy caused an increase in cardiac output and a decrease in left ventricular end-diastolic pressure without chronotropic or significant metabolic effects. DITPA treatment induces arteriolar growth and improves maximal perfusion potential of hypertrophied myocardium surviving a myocardial infarction. Thyroid hormone receptor-β-selective agonists, GC-24, KB-141, and KAT-681, as well as the thyroid hormone receptor-α-selective and thyroid hormone receptor-β-selective antagonists dronedarone and NH-3 show promise in treating hypercholesterolemia, hyperlipidemia, hepatocarcinogenesis, heart failure, and hyperthyroidism. Summary: Thyroid hormone receptors orchestrate a diverse array of physiologic activities in an isoform-specific manner. These activities include fetal and postnatal development, regulation of lipid inventory, and effects on cardiac performance. As a result, thyroid hormone analogues that selectively modulate thyroid hormone receptor isoforms serve as potential therapeutics in treating several metabolic and cardiac-related diseases.

AB - Purpose of review: Scientists have been studying liver-selective thyroid hormone analogues developed between the late 1980s through the late 1990s to validate their utility in treating hypercholesterolemia, diabetes, atherosclerosis, and obesity. Several thyromimetics with agonistic or antagonist properties have recently been developed and their clinical utility is being explored. This review presents the progress of several thyromimetics with potential clinical utility and provides an assessment of the potential of second-generation thyromimetics with varying pharmacologic profiles. Recent findings: GC-1 exhibits cholesterol-lowering effects in hypothyroid mice, cholesterol-fed rats, and cynomolgus monkeys. DITPA (3,5-diiodothyropropionic acid) is currently being investigated for use in treating congestive heart failure. In rat and rabbit postinfarction models, DITPA administration in combination with captopril or as monotherapy caused an increase in cardiac output and a decrease in left ventricular end-diastolic pressure without chronotropic or significant metabolic effects. DITPA treatment induces arteriolar growth and improves maximal perfusion potential of hypertrophied myocardium surviving a myocardial infarction. Thyroid hormone receptor-β-selective agonists, GC-24, KB-141, and KAT-681, as well as the thyroid hormone receptor-α-selective and thyroid hormone receptor-β-selective antagonists dronedarone and NH-3 show promise in treating hypercholesterolemia, hyperlipidemia, hepatocarcinogenesis, heart failure, and hyperthyroidism. Summary: Thyroid hormone receptors orchestrate a diverse array of physiologic activities in an isoform-specific manner. These activities include fetal and postnatal development, regulation of lipid inventory, and effects on cardiac performance. As a result, thyroid hormone analogues that selectively modulate thyroid hormone receptor isoforms serve as potential therapeutics in treating several metabolic and cardiac-related diseases.

KW - Cardiac sparing

KW - Hypercholesterolemia

KW - Isoform specific

KW - Liver selective

KW - Thyroid hormone analogues

KW - Thyroid hormone receptor

KW - Thyromimetics

UR - http://www.scopus.com/inward/record.url?scp=26444526576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444526576&partnerID=8YFLogxK

U2 - 10.1097/01.med.0000177422.57988.b2

DO - 10.1097/01.med.0000177422.57988.b2

M3 - Article

AN - SCOPUS:26444526576

VL - 12

SP - 363

EP - 370

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 5

ER -